Growth hormone co-treatment for ovulation induction may enhance conception in the co-treatment and succeeding cycles, in clonidine negative but not clonidine positive patients.
To investigate the effect of co-treatment with growth hormone (GH) for ovulation induction with human menopausal gonadotrophins (HMG) on conception, we compared the pregnancy rate and response to co-treatment with GH versus HMG/human chorionic gonadotrophin (HCG) alone in a prospective, randomized, cross-over protocol of ovulation induction for either in-vivo or in-vitro fertilization (IVF). The main outcome measures were the amount of gonadotrophin used and conception. Co-treatment with GH was associated with a reduction of approximately 30% in gonadotrophin requirement. In 24 clonidine negative patients 14 pregnancies were achieved (58.3%) either in the GH/HMG/HCG cycle or in the succeeding one. GH co-treatment did not generate any pregnancy in eight clonidine positive patients. We conclude that growth hormone may increase the pregnancy rate when combined with HMG/HCG for ovulation induction, not only in the co-treatment cycle but also in the succeeding one. The beneficial, synergistic effect of GH co-treatment was detected in clonidine negative but not in clonidine positive infertile patients.
Blumenfeld
Z
Z
Department of Obstetrics and Gynaecology, Rambam Medical Centre, Haifa, Israel.
Dirnfeld
M
M
Gonen
Y
Y
Abramovici
H
H
D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D003000:Clonidine; D004359:Drug Therapy, Combination; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D008596:Menotropins / Q000008:administration & dosage*; D008597:Menstrual Cycle / Q000187:drug effects*; D010062:Ovulation Induction / Q000379:methods*; D011237:Predictive Value of Tests; D011446:Prospective Studies
D006063:Chorionic Gonadotropin; D008596:Menotropins; D013006:Growth Hormone; D003000:Clonidine